Welcome to our dedicated page for Caribou Biosciences news (Ticker: CRBU), a resource for investors and traders seeking the latest updates and insights on Caribou Biosciences stock.
Caribou Biosciences develops CRISPR genome-edited, allogeneic CAR-T cell therapies for hematologic malignancies. Company updates center on vispacabtagene regedleucel, or vispa-cel, an anti-CD19 CAR-T therapy being evaluated in B cell non-Hodgkin lymphoma and large B cell lymphoma, and CB-011, an anti-BCMA CAR-T therapy for relapsed or refractory multiple myeloma.
Recurring announcements include clinical and translational data from the ANTLER and CaMMouflage trials, FDA designations and trial-design interactions, financial results, research and development spending, cash resources, pipeline prioritization, and medical or investor conference participation.
Summary not available.
Summary not available.
Caribou Biosciences (Nasdaq: CRBU) announced promising preclinical results for CB-012, a CRISPR-edited CAR-T cell therapy targeting relapsed or refractory acute myeloid leukemia (r/r AML), during the 2023 AACR Annual Meeting. The study indicated CB-012 shows enhanced antitumor activity, prolonged survival in AML xenograft models, and protective immune cloaking against NK cell-mediated cytotoxicity. The therapy is engineered with advanced Cas12a chRDNA technology, enabling five genomic edits for improved efficacy. Caribou plans to submit an IND application for CB-012 in H2 2023, signaling a key step in its clinical development strategy. CEO Rachel Haurwitz stated the data supports advancing CB-012 for clinical trials.
Caribou Biosciences (Nasdaq: CRBU) announced that the FDA has granted Fast Track designation to its investigational therapy, CB-011, for treating relapsed or refractory multiple myeloma (r/r MM). This designation facilitates communication with the FDA during the clinical review process. The CaMMouflage Phase 1 trial, which has recently commenced patient dosing, aims to develop CB-011 as an accessible off-the-shelf treatment option, eliminating the need for lengthy manufacturing and complex procedures. CB-011, derived from Caribou's CAR-T platform, employs advanced genome-editing techniques to enhance antitumor capabilities. The company continues to focus on developing cutting-edge therapies for serious diseases.
Caribou Biosciences (Nasdaq: CRBU) announced the first patient has been dosed in the CaMMouflage Phase 1 trial of CB-011, an allogeneic anti-BCMA CAR-T cell therapy aimed at patients with relapsed or refractory multiple myeloma. This trial seeks to evaluate the safety and efficacy of the therapy, utilizing an innovative immune cloaking strategy to enhance antitumor activity by mitigating rejection from T and natural killer cells. As part of Caribou's aim to address unmet needs in treatment accessibility, the trial will include adults with extensive prior therapies. The company plans to continue patient enrollment to assess CB-011's therapeutic potential.
Caribou Biosciences, Inc. (Nasdaq: CRBU) announced the start of the dose expansion phase of its CB-010 ANTLER trial for second-line large B cell lymphoma (LBCL) patients. CB-010 is the first allogeneic CAR-T therapy assessed in this setting. The dose escalation was well tolerated, with no dose-limiting toxicities observed at the highest dose level. Earlier cohorts showed promising results, with complete responses in 6 out of 6 patients treated. The trial will evaluate two dose levels on about 30 patients to establish the recommended Phase 2 dose and aims to address the challenges associated with autologous therapies. An update is expected in H2 2023.
Caribou Biosciences (CRBU) reported Q4 and full-year 2022 results, highlighting ongoing progress in its clinical pipeline. As of December 31, 2022, the company held $317 million in cash and equivalents, sufficient to fund operations into 2025. The lead therapy, CB-010, showed promising results in treating relapsed/refractory B-cell non-Hodgkin lymphoma, with notable complete response rates. Recent advancements include the activation of clinical sites for CB-011 and the initiation of IND-enabling studies for CB-012, targeting acute myeloid leukemia. However, a net loss of $99.4 million for 2022 raises concerns.
Caribou Biosciences (Nasdaq: CRBU), a leader in CRISPR genome-editing, announced that its CEO, Rachel Haurwitz, will participate in a fireside chat at the Oppenheimer 33rd Annual Healthcare Conference on March 15, 2023, at 10:40 am EDT. This event will showcase Caribou's advancements in gene-editing technologies, particularly their innovative CRISPR hybrid RNA-DNA guides (chRDNAs), aimed at enhancing precision in genome editing. The live webcast can be accessed on Caribou's website, available for 30 days post-event. The company focuses on developing transformative therapies for serious diseases using its proprietary technology.
Caribou Biosciences (Nasdaq: CRBU) announced that CEO Rachel Haurwitz, Ph.D., will participate in three upcoming investor conferences in February 2023. The conferences include the Guggenheim Oncology Conference on February 9 at 10:45 AM EST, the SVB Securities Global Biopharma Conference on February 14 at 5:00 PM EST, and Citi's 2023 Oncology Leadership Summit on February 22 at 2:00 PM EST. All events offer webcasts for attendees. Caribou is known for its next-generation CRISPR genome-editing platform, particularly its innovative chRDNA technology, enhancing precision in therapies for hematologic malignancies and solid tumors.
Caribou Biosciences, Inc. (Nasdaq: CRBU) will present a corporate update by CEO Rachel Haurwitz at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 11:15 am PST. A live webcast will be available on Caribou's website, with an archived version accessible for 30 days post-event. Caribou is focused on advancing CRISPR genome-editing technologies, specifically its chRDNA platform, to develop innovative therapies for cancer treatment.